



Clinical trial results:

An exploratory study to investigate the optimal scheduling of chemotherapy in patients with operable colorectal liver metastases

Summary

EudraCT number	2011-003052-40
Trial protocol	GB
Global end of trial date	31 July 2015

Results information

Result version number	v1 (current)
This version publication date	06 March 2024
First version publication date	06 March 2024

Trial information

Trial identification

Sponsor protocol code	RHMCAN0763
-----------------------	------------

Additional study identifiers

ISRCTN number	ISRCTN32401805
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	University Hospital Southampton NHS Foundation Trust
Sponsor organisation address	Southampton General Hospital, Level E, Laboratory & Pathology Block, SCBR, MP 138, Southampton, United Kingdom, SO16 6YD
Public contact	University of Southampton Clinical Trials Unit, University of Southampton Clinical Trials Unit, 0044 2381205154, ctu@soton.ac.uk
Scientific contact	University of Southampton Clinical Trials Unit, University of Southampton Clinical Trials Unit, 0044 2381205154, ctu@soton.ac.uk

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	01 May 2013
Is this the analysis of the primary completion data?	Yes
Primary completion date	01 May 2013
Global end of trial reached?	Yes
Global end of trial date	31 July 2015
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

Currently some patients with colorectal cancer that has spread to the liver can be treated surgically and a significant number will effectively be cured. A prior study has shown that chemotherapy improves the survival of these patients if it is given both before and after the liver surgery. However this causes an increase in the complications of surgery. In this trial we are trying to find out if giving all the chemotherapy after surgery is possible, hence potentially avoiding this problem of complications. If this approach is feasible a larger trial will be undertaken to see if this approach is equivalent in terms of the long term survival of these patients.

Protection of trial subjects:

Eligible participants for the trials were aged 18 years or older, with metastatic resectable liver-limited colorectal cancer, and were recruited from approved study sites. Resectability was confirmed by a liver surgeon and the protocols mandated this as completely removable disease with a microscopic margin of >1 mm achievable and an estimated preoperative margin of ≥ 5 mm. The number of tumors was not restricted. All studies were performed in accordance with the Declaration of Helsinki. Institutional or central ethics and research governance approval was obtained, and patients provided written informed consent.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	01 November 2011
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United Kingdom: 20
Worldwide total number of subjects	20
EEA total number of subjects	20

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0

Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	20
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Eligible participants for the trials were aged 18 years or older, with metastatic resectable liver-limited colorectal cancer, and were recruited from approved study sites. Resectability was confirmed by a liver surgeon and the protocols mandated this as completely removable disease with a microscopic margin of >1 mm achievable

Pre-assignment

Screening details:

Participants were randomized to receive three months of preoperative and three months of postoperative treatment or six months of postoperative treatment with FOLFOX6 (5-fluorouracil plus oxaliplatin) every two weeks, FOLFIRI (5-fluorouracil plus irinotecan) every two weeks, or CAPOX every three weeks

Period 1

Period 1 title	Overall study period (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Surgery, than chemotherapy

Arm description:

Surgery, than 24weeks standard chemotherapy

Arm type	Experimental
Investigational medicinal product name	mFOLFOX
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate and solvent for solution for infusion
Routes of administration	Infusion

Dosage and administration details:

24 weeks

Investigational medicinal product name	CAPOX
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate and solvent for solution for infusion
Routes of administration	Infusion

Dosage and administration details:

24 weeks

Investigational medicinal product name	mFOLFIRI
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate and solvent for solution for infusion
Routes of administration	Infusion

Dosage and administration details:

24 weeks

Arm title	12weeks chemo, surgery, 12 weeks chemo
------------------	--

Arm description:

12 weeks (peri-operative) standard chemotherapy, surgery, 12 weeks (post-operative) standard chemotherapy

Arm type	Experimental
----------	--------------

Investigational medicinal product name	mFOLFOX
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate and solvent for solution for infusion
Routes of administration	Infusion
Dosage and administration details:	
24 weeks (12 weeks pre and post operative)	
Investigational medicinal product name	CAPOX
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate and solvent for solution for infusion
Routes of administration	Infusion
Dosage and administration details:	
24 weeks (12 weeks pre and post operative)	

Number of subjects in period 1	Surgery, than chemotherapy	12weeks chemo, surgery, 12 weeks chemo
Started	10	10
Completed	7	3
Not completed	3	7
didnt complete the chemotherapy	2	-
progress before surgery	-	3
no surgical information	-	1
early termination by Sponsor, no surgery	-	1
not completing the postop chemotherapy	-	2
incorrect randomisation	1	-

Baseline characteristics

Reporting groups

Reporting group title	Surgery, than chemotherapy
-----------------------	----------------------------

Reporting group description:

Surgery, than 24weeks standard chemotherapy

Reporting group title	12weeks chemo, surgery, 12 weeks chemo
-----------------------	--

Reporting group description:

12 weeks (peri-operative) standard chemotherapy, surgery, 12 weeks (post-operative) standard chemotherapy

Reporting group values	Surgery, than chemotherapy	12weeks chemo, surgery, 12 weeks chemo	Total
Number of subjects	10	10	20
Age categorical			
Units: Subjects			
Age 18-69	9	10	19
Unknown	1	0	1
Age continuous			
Units: years			
median	65	64	
inter-quartile range (Q1-Q3)	61 to 69	58 to 66	-
Gender categorical			
Units: Subjects			
Female	5	2	7
Male	4	8	12
Unknown	1	0	1

End points

End points reporting groups

Reporting group title	Surgery, than chemotherapy
Reporting group description: Surgery, than 24weeks standard chemotherapy	
Reporting group title	12weeks chemo, surgery, 12 weeks chemo
Reporting group description: 12 weeks (peri-operative) standard chemotherapy, surgery, 12 weeks (post-operative) standard chemotherapy	

Primary: Recruitment feasibility

End point title	Recruitment feasibility ^[1]
End point description:	
End point type	Primary
End point timeframe: 32 months	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No sufficient number for statistical analyses, early termination of the trial.

End point values	Surgery, than chemotherapy	12weeks chemo, surgery, 12 weeks chemo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	10 ^[2]	10 ^[3]		
Units: Number of patient finished the trial	7	3		

Notes:

[2] - Recruited patients

[3] - Recruited patients

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of chemotherapy cycles

End point title	Proportion of chemotherapy cycles
End point description:	
End point type	Secondary
End point timeframe: 32 months	

End point values	Surgery, than chemotherapy	12weeks chemo, surgery, 12 weeks chemo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9 ^[4]	10		
Units: Cycles	12	6		

Notes:

[4] - 1 person withdrawn because of wrong randomisation

Statistical analyses

No statistical analyses for this end point

Secondary: Surgical mortality and complications

End point title	Surgical mortality and complications
End point description:	
End point type	Secondary
End point timeframe:	
within 30 days after the surgery	

End point values	Surgery, than chemotherapy	12weeks chemo, surgery, 12 weeks chemo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9 ^[5]	5 ^[6]		
Units: number of patients with complications	2	4		

Notes:

[5] - number of patient went through surgery

[6] - number of patient went through surgery

Statistical analyses

No statistical analyses for this end point

Secondary: Treatment related toxicity

End point title	Treatment related toxicity
End point description:	
End point type	Secondary
End point timeframe:	
32 months	

End point values	Surgery, than chemotherapy	12weeks chemo, surgery, 12 weeks chemo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9 ^[7]	10		
Units: patients had treatment related adverse	8	10		

Notes:

[7] - 1 person withdrawn because of wrong randomisation

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Timeframe for AE

Adverse event reporting additional description:

AE additional description

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	19.0
--------------------	------

Reporting groups

Reporting group title	Arm A
-----------------------	-------

Reporting group description: -

Reporting group title	Arm B
-----------------------	-------

Reporting group description: -

Serious adverse events	Arm A	Arm B	
Total subjects affected by serious adverse events			
subjects affected / exposed	3 / 9 (33.33%)	2 / 10 (20.00%)	
number of deaths (all causes)	1	2	
number of deaths resulting from adverse events	0	0	
General disorders and administration site conditions			
Fever	Additional description: Fever		
subjects affected / exposed	1 / 9 (11.11%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain	Additional description: Pain		
subjects affected / exposed	1 / 9 (11.11%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Obstruction gastric	Additional description: Obstruction gastric		
subjects affected / exposed	1 / 9 (11.11%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain	Additional description: Abdominal pain		

subjects affected / exposed	1 / 9 (11.11%)	1 / 10 (10.00%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Hepatic pain	Additional description: Hepatic pain		
subjects affected / exposed	1 / 9 (11.11%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Productive cough	Additional description: Productive cough		
subjects affected / exposed	0 / 9 (0.00%)	1 / 10 (10.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Arm A	Arm B	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	8 / 9 (88.89%)	10 / 10 (100.00%)	
Vascular disorders			
Thromboembolic event	Additional description: Thromboembolic event		
subjects affected / exposed	1 / 9 (11.11%)	1 / 10 (10.00%)	
occurrences (all)	2	1	
Hematoma	Additional description: Hematoma		
subjects affected / exposed	0 / 9 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
Flushing	Additional description: Flushing		
subjects affected / exposed	2 / 9 (22.22%)	0 / 10 (0.00%)	
occurrences (all)	2	0	
General disorders and administration site conditions			
Injection site reaction	Additional description: Injection site reaction		
subjects affected / exposed	1 / 9 (11.11%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Edema limbs	Additional description: Edema limbs		

subjects affected / exposed	0 / 9 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
Fever	Additional description: Fever		
subjects affected / exposed	0 / 9 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
Fatigue	Additional description: Fatigue		
subjects affected / exposed	6 / 9 (66.67%)	4 / 10 (40.00%)	
occurrences (all)	19	9	
Pain	Additional description: Pain		
subjects affected / exposed	4 / 9 (44.44%)	7 / 10 (70.00%)	
occurrences (all)	6	11	
Respiratory, thoracic and mediastinal disorders			
Pneumothorax	Additional description: Pneumothorax		
subjects affected / exposed	0 / 9 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
Laryngopharyngeal dysesthesia	Additional description: Laryngopharyngeal dysesthesia		
subjects affected / exposed	0 / 9 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
Cough	Additional description: Cough		
subjects affected / exposed	0 / 9 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
Epistaxis	Additional description: Epistaxis		
subjects affected / exposed	3 / 9 (33.33%)	1 / 10 (10.00%)	
occurrences (all)	4	1	
Sore throat	Additional description: Sore throat		
subjects affected / exposed	0 / 9 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	2	
Dyspnea	Additional description: Dyspnea		
subjects affected / exposed	1 / 9 (11.11%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Productive cough	Additional description: Productive cough		
subjects affected / exposed	0 / 9 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
Psychiatric disorders			

Anxiety subjects affected / exposed occurrences (all)	Additional description: Anxiety	
	0 / 9 (0.00%) 0	1 / 10 (10.00%) 1
Depression subjects affected / exposed occurrences (all)	Additional description: Depression	
	1 / 9 (11.11%) 2	1 / 10 (10.00%) 1
Insomnia subjects affected / exposed occurrences (all)	Additional description: Insomnia	
	1 / 9 (11.11%) 1	0 / 10 (0.00%) 0
Psychiatric disorders - Other, specify subjects affected / exposed occurrences (all)	Additional description: Psychiatric disorders - Other, specify	
	0 / 9 (0.00%) 0	2 / 10 (20.00%) 2
Investigations		
Neutrophil count decreased subjects affected / exposed occurrences (all)	Additional description: Neutrophil count decreased	
	5 / 9 (55.56%) 8	3 / 10 (30.00%) 3
Weight loss subjects affected / exposed occurrences (all)	Additional description: Weight loss	
	0 / 9 (0.00%) 0	2 / 10 (20.00%) 2
Platelet count decreased subjects affected / exposed occurrences (all)	Additional description: Platelet count decreased	
	4 / 9 (44.44%) 5	5 / 10 (50.00%) 6
Hemoglobin increased subjects affected / exposed occurrences (all)	Additional description: Hemoglobin increased	
	0 / 9 (0.00%) 0	1 / 10 (10.00%) 1
Blood bilirubin increased subjects affected / exposed occurrences (all)	Additional description: Blood bilirubin increased	
	0 / 9 (0.00%) 0	1 / 10 (10.00%) 1
White blood cell decreased subjects affected / exposed occurrences (all)	Additional description: White blood cell decreased	
	3 / 9 (33.33%) 3	3 / 10 (30.00%) 4
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	Additional description: Alanine aminotransferase increased	
	1 / 9 (11.11%) 1	0 / 10 (0.00%) 0
Injury, poisoning and procedural complications		

Fall subjects affected / exposed occurrences (all)	Additional description: Fall		
	1 / 9 (11.11%)	0 / 10 (0.00%)	
	1	0	
Wound complication subjects affected / exposed occurrences (all)	Additional description: Wound complication		
	0 / 9 (0.00%)	1 / 10 (10.00%)	
	0	1	
Cardiac disorders			
Palpitations subjects affected / exposed occurrences (all)	Additional description: Palpitations		
	1 / 9 (11.11%)	0 / 10 (0.00%)	
	1	0	
Atrial fibrillation subjects affected / exposed occurrences (all)	Additional description: Atrial fibrillation		
	0 / 9 (0.00%)	1 / 10 (10.00%)	
	0	1	
Nervous system disorders			
Peripheral sensory neuropathy subjects affected / exposed occurrences (all)	Additional description: Peripheral sensory neuropathy		
	1 / 9 (11.11%)	1 / 10 (10.00%)	
	1	4	
Dysgeusia subjects affected / exposed occurrences (all)	Additional description: Dysgeusia		
	4 / 9 (44.44%)	4 / 10 (40.00%)	
	4	7	
Nervous system disorders - Other, specify subjects affected / exposed occurrences (all)	Additional description: Nervous system disorders - Other, specify		
	7 / 9 (77.78%)	9 / 10 (90.00%)	
	22	20	
Paresthesia subjects affected / exposed occurrences (all)	Additional description: Paresthesia		
	0 / 9 (0.00%)	2 / 10 (20.00%)	
	0	2	
Headache subjects affected / exposed occurrences (all)	Additional description: Headache		
	0 / 9 (0.00%)	2 / 10 (20.00%)	
	0	2	
Neuralgia subjects affected / exposed occurrences (all)	Additional description: Neuralgia		
	2 / 9 (22.22%)	4 / 10 (40.00%)	
	2	4	
Lethargy subjects affected / exposed occurrences (all)	Additional description: Lethargy		
	1 / 9 (11.11%)	5 / 10 (50.00%)	
	1	7	
Dysesthesia	Additional description: Dysesthesia		

subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 10 (0.00%) 0	
Dizziness	Additional description: Dizziness		
subjects affected / exposed occurrences (all)	2 / 9 (22.22%) 2	0 / 10 (0.00%) 0	
Blood and lymphatic system disorders			
Blood and lymphatic system disorders - Other, specify	Additional description: Blood and lymphatic system disorders - Other, specify		
subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	1 / 10 (10.00%) 1	
Anemia	Additional description: Anemia		
subjects affected / exposed occurrences (all)	7 / 9 (77.78%) 8	5 / 10 (50.00%) 6	
Febrile neutropenia	Additional description: Febrile neutropenia		
subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 10 (10.00%) 1	
Ear and labyrinth disorders			
Middle ear inflammation	Additional description: Middle ear inflammation		
subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 10 (0.00%) 0	
Tinnitus	Additional description: Tinnitus		
subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 10 (10.00%) 1	
Ear pain	Additional description: Ear pain		
subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 10 (10.00%) 3	
Eye disorders			
Eye disorders - Other, specify	Additional description: Eye disorders - Other, specify		
subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 10 (10.00%) 1	
Watering eyes	Additional description: Watering eyes		
subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 10 (10.00%) 1	
Gastrointestinal disorders			
Nausea	Additional description: Nausea		
subjects affected / exposed occurrences (all)	6 / 9 (66.67%) 21	7 / 10 (70.00%) 12	

Dyspepsia	Additional description: Dyspepsia	
subjects affected / exposed	1 / 9 (11.11%)	0 / 10 (0.00%)
occurrences (all)	1	0
Vomiting	Additional description: Vomiting	
subjects affected / exposed	4 / 9 (44.44%)	1 / 10 (10.00%)
occurrences (all)	5	1
Abdominal pain	Additional description: Abdominal pain	
subjects affected / exposed	1 / 9 (11.11%)	2 / 10 (20.00%)
occurrences (all)	1	4
Gastrointestinal disorders - Other, specify	Additional description: Gastrointestinal disorders - Other, specify	
subjects affected / exposed	3 / 9 (33.33%)	1 / 10 (10.00%)
occurrences (all)	4	1
Flatulence	Additional description: Flatulence	
subjects affected / exposed	1 / 9 (11.11%)	0 / 10 (0.00%)
occurrences (all)	1	0
Dry mouth	Additional description: Dry mouth	
subjects affected / exposed	1 / 9 (11.11%)	0 / 10 (0.00%)
occurrences (all)	2	0
Abdominal distension	Additional description: Abdominal distension	
subjects affected / exposed	1 / 9 (11.11%)	0 / 10 (0.00%)
occurrences (all)	1	0
Diarrhea	Additional description: Diarrhea	
subjects affected / exposed	7 / 9 (77.78%)	7 / 10 (70.00%)
occurrences (all)	18	12
Constipation	Additional description: Constipation	
subjects affected / exposed	4 / 9 (44.44%)	4 / 10 (40.00%)
occurrences (all)	6	6
Small intestinal obstruction	Additional description: Small intestinal obstruction	
subjects affected / exposed	0 / 9 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	1
Anal pain	Additional description: Anal pain	
subjects affected / exposed	0 / 9 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	1
Hemorrhoids	Additional description: Hemorrhoids	

subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 10 (10.00%) 1	
Mucositis oral	Additional description: Mucositis oral		
subjects affected / exposed occurrences (all)	4 / 9 (44.44%) 8	2 / 10 (20.00%) 6	
Skin and subcutaneous tissue disorders			
Dry skin	Additional description: Dry skin		
subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	1 / 10 (10.00%) 1	
Skin and subcutaneous tissue disorders - Other, specify	Additional description: Skin and subcutaneous tissue disorders - Other, specify		
subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	4 / 10 (40.00%) 4	
Alopecia	Additional description: Alopecia		
subjects affected / exposed occurrences (all)	2 / 9 (22.22%) 2	4 / 10 (40.00%) 4	
Rash maculo-papular	Additional description: Rash maculo-papular		
subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 10 (10.00%) 1	
Palmar-plantar erythrodysesthesia syndrome	Additional description: Palmar-plantar erythrodysesthesia syndrome		
subjects affected / exposed occurrences (all)	2 / 9 (22.22%) 2	3 / 10 (30.00%) 5	
Pruritus	Additional description: Pruritus		
subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	0 / 10 (0.00%) 0	
Purpura	Additional description: Purpura		
subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 10 (10.00%) 1	
Musculoskeletal and connective tissue disorders			
Pain in extremity	Additional description: Pain in extremity		
subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	1 / 10 (10.00%) 4	
Myalgia	Additional description: Myalgia		
subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 10 (10.00%) 1	
Back pain	Additional description: Back pain		

subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	1 / 10 (10.00%) 1	
Arthralgia	Additional description: Arthralgia		
subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 10 (10.00%) 1	
Arthritis	Additional description: Arthritis		
subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 10 (10.00%) 1	
Infections and infestations			
Mucosal infection	Additional description: Mucosal infection		
subjects affected / exposed occurrences (all)	2 / 9 (22.22%) 4	1 / 10 (10.00%) 1	
Upper respiratory infection	Additional description: Upper respiratory infection		
subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 10 (10.00%) 1	
Wound infection	Additional description: Wound infection		
subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 10 (10.00%) 2	
Tooth infection	Additional description: Tooth infection		
subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 10 (10.00%) 1	
Infections and infestations - Other, specify	Additional description: Infections and infestations - Other, specify		
subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 2	4 / 10 (40.00%) 4	
Stoma site infection	Additional description: Stoma site infection		
subjects affected / exposed occurrences (all)	3 / 9 (33.33%) 4	3 / 10 (30.00%) 3	
Metabolism and nutrition disorders			
Anorexia	Additional description: Anorexia		
subjects affected / exposed occurrences (all)	1 / 9 (11.11%) 1	6 / 10 (60.00%) 9	
Hypokalemia	Additional description: Hypokalemia		
subjects affected / exposed occurrences (all)	0 / 9 (0.00%) 0	1 / 10 (10.00%) 1	
Hyponatremia	Additional description: Hyponatremia		

subjects affected / exposed	1 / 9 (11.11%)	0 / 10 (0.00%)	
occurrences (all)	1	0	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported